1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

SSSE:688513
46.28
CNY
+1.23
(+2.73%)
1.38EPS
28.43P/E
7.76BMarket Cap
Oct 28Next Earn
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A
SSE:688513
(Shanghai Stock Exchange)

Recent

price

46.28

P/E

ratio

28.43

div

yld

2.00%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.23
1.7
1.87
2.65
3.62
5.81
7.18
6.27
5.81
6.62
6.31
7.71
7.64
7.57
Revenue per Share
0.11
0.24
0.29
0.45
0.49
1.02
0.82
1.21
1.32
1.39
1.28
1.36
1.63
1.55
Basic EPS, GAAP
-0.36
0.2
0.14
0.69
0.48
0.68
0.35
-0.29
-0.62
-1.06
0.56
0.83
1.03
- -
Free Cash Flow per Basic Share
0.02
0.02
- -
- -
0.17
- -
0.17
- -
0.21
0.54
0.4
0.42
0.44
0.93
Dividend per Share
1.19
1.42
1.85
2.95
3.37
4.4
5.27
11.87
12.98
13.85
14.75
15.28
16.61
16.62
Book Value per Share
1.07
1.3
1.73
2.84
3.25
4.13
5.01
11.68
12.75
13.41
14.27
14.66
14.78
14.79
Tangible Book Value per Share
132
123
129
128
131
132
132
147
176
177
177
175
174
174
Basic Weighted Avg Shares
162
209
241
339
476
769
947
922
1,023
1,171
1,117
1,350
1,331
1,320
Sales/Revenue/Turnover
8.48
15.07
17.33
11.73
15.53
19.17
11.75
20.64
19.34
19.32
18.55
16.42
18.97
17.09
Operating Margin (%)
8
13
20
22
24
25
28
33
33
58
73
83
93
- -
Depreciation Expense
15
29
38
57
64
135
109
178
232
247
227
238
284
270
Net Income, GAAP
6.72
14.7
14.34
12.51
13.57
8.97
6.3
10.49
5.87
5.9
6.23
5.68
8.7
13.48
Effective Tax Rate (%)
9.07
14
15.63
16.92
13.51
17.56
11.47
19.33
22.72
21.06
20.28
17.65
21.34
20.43
Profit Margin (%)
2
14
75
210
277
336
354
1,509
1,347
1,180
1,222
1,332
1,513
1,496
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
40
36
32
29
LT Debt
157
187
244
390
445
582
697
2,095
2,292
2,444
2,603
2,698
3,039
3,022
Total Equity
- -
11.64
15.43
10.66
15.07
26
16.51
12.46
10.29
10.05
8.41
8.4
9.52
8.28
Return on Invested Capital (%)
- -
14.41
16.62
17.99
15.22
25.89
16.73
12.6
10.47
10.24
8.55
8.57
9.9
9.53
Return on Capital (%)
- -
16.96
17.43
18.08
15.42
26.28
16.98
12.76
10.6
10.41
8.98
8.99
10.09
9.47
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
115
50
119
LT Borrowings
32
32
29
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
177
177
177
Market Capitalization
10,866
11,367
7,760

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,132
2,117
2,162
Cash, Cash Equivalents & STI
1,613
1,622
1,673
Accounts Receivable, Net
181
178
167
Inventories
229
247
248
Total Current Liabilities
619
554
666
Payables & Accruals
- -
- -
- -
ST Debt
115
50
119
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.36%
7.76%
12.64%
Free Cash Flow
30.49%
28.89%
22.52%
Net Income, GAAP
27.17%
10.56%
19.24%
Sales/Revenue/Turnover
20.36%
8.06%
-1.36%
Total Cash Common Dividend
- -
1,054.61%
3.62%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
315
355
370
310
1,350
2025
306
349
- -
312
1,331
2026
326
333
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.43
0.28
0.4
0.12
1.36
2025
0.34
0.44
- -
0.37
1.63
2026
0.29
0.45
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.16
0.17
- -
0.42
2025
- -
0.43
- -
- -
0.44
2026
- -
0.49
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Chengdu Easton Biopharmaceuticals Co., Ltd. focuses its operations on the discovery, development, production, and commercialization of various pharmaceutical solutions. The company delivers comprehensive finished pharmaceutical preparations, encompassing areas such as pain management, cardiovascular health, oncology, and pediatric care. Additionally, it supplies a broad portfolio of active pharmaceutical ingredients across therapeutic categories including oncology, cardiovascular conditions, anesthetics, anti-inflammatory agents, gastrointestinal issues, and neurological disorders. Founded in 2009, this enterprise is strategically located in Chengdu, China.